Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATON NASDAQ:GRTX NASDAQ:LNAI NASDAQ:SLXN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATONPortage Biotech$0.33+3.8%$0.35$0.28▼$13.80$7.78M0.493.17 million shs9.78 million shsGRTXGalera Therapeutics$0.10$0.06$0.02▼$0.15$7.55M2.64238,349 shs112,627 shsLNAILunai Bioworks$0.33-0.9%$0.35$0.15▼$5.50$8.05M0.3410.13 million shs1.19 million shsSLXNSilexion Therapeutics$0.53+1.2%$1.25$0.47▼$22.36$1.73M-0.2987,130 shs129,428 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATONPortage Biotech0.00%0.00%+4.60%-38.06%+33,199,900.00%GRTXGalera Therapeutics0.00%0.00%+142.72%+354.55%+336.68%LNAILunai Bioworks0.00%+0.91%-6.72%-49.73%+33,299,900.00%SLXNSilexion Therapeutics0.00%-15.21%-53.66%-67.76%-96.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATONPortage Biotech$0.33+3.8%$0.35$0.28▼$13.80$7.78M0.493.17 million shs9.78 million shsGRTXGalera Therapeutics$0.10$0.06$0.02▼$0.15$7.55M2.64238,349 shs112,627 shsLNAILunai Bioworks$0.33-0.9%$0.35$0.15▼$5.50$8.05M0.3410.13 million shs1.19 million shsSLXNSilexion Therapeutics$0.53+1.2%$1.25$0.47▼$22.36$1.73M-0.2987,130 shs129,428 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATONPortage Biotech0.00%0.00%+4.60%-38.06%+33,199,900.00%GRTXGalera Therapeutics0.00%0.00%+142.72%+354.55%+336.68%LNAILunai Bioworks0.00%+0.91%-6.72%-49.73%+33,299,900.00%SLXNSilexion Therapeutics0.00%-15.21%-53.66%-67.76%-96.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATONPortage Biotech 2.00Hold$2.00502.41% UpsideGRTXGalera Therapeutics 0.00N/AN/AN/ALNAILunai Bioworks 1.00SellN/AN/ASLXNSilexion Therapeutics 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest SLXN, ATON, GRTX, and LNAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2026LNAILunai Bioworks Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/18/2026SLXNSilexion Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)2/24/2026ATONPortage Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$2.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATONPortage BiotechN/AN/AN/AN/A($0.79) per shareN/AGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/ALNAILunai BioworksN/AN/AN/AN/A($1.24) per shareN/ASLXNSilexion TherapeuticsN/AN/AN/AN/A$0.83 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATONPortage Biotech-$6.77M-$8.18N/AN/AN/AN/AN/AN/AN/AGRTXGalera Therapeutics-$59.08M$0.64N/AN/AN/AN/AN/A-99.34%5/11/2026 (Estimated)LNAILunai Bioworks-$178.01M$0.056.60N/AN/AN/A-1,243.45%-360.31%N/ASLXNSilexion Therapeutics-$11.91M-$11.10N/AN/AN/AN/A-387.82%-144.68%5/12/2026 (Estimated)Latest SLXN, ATON, GRTX, and LNAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026N/ASLXNSilexion Therapeutics-$1.29N/AN/AN/AN/AN/A5/11/2026N/AGRTXGalera Therapeutics-$0.8313N/AN/AN/AN/AN/A2/17/2026Q2 2026LNAILunai BioworksN/A-$0.08N/A-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATONPortage BiotechN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/ALNAILunai BioworksN/AN/AN/AN/AN/ASLXNSilexion TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATONPortage BiotechN/A0.880.88GRTXGalera TherapeuticsN/A9.749.74LNAILunai BioworksN/A0.030.03SLXNSilexion Therapeutics0.602.412.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATONPortage Biotech13.36%GRTXGalera Therapeutics50.77%LNAILunai Bioworks71.41%SLXNSilexion Therapeutics10.95%Insider OwnershipCompanyInsider OwnershipATONPortage BiotechN/AGRTXGalera Therapeutics12.90%LNAILunai Bioworks0.50%SLXNSilexion Therapeutics5.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATONPortage Biotech623.44 millionN/AN/AGRTXGalera Therapeutics3075.46 million47.38 millionOptionableLNAILunai Bioworks2024.19 million24.07 millionN/ASLXNSilexion TherapeuticsN/A3.33 million3.16 millionN/ASLXN, ATON, GRTX, and LNAI HeadlinesRecent News About These CompaniesSilexion Therapeutics (NASDAQ:SLXN) Stock Price Down 2.3% - What's Next?May 2, 2026 | americanbankingnews.comSilexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic CancerApril 28, 2026 | markets.businessinsider.comSilexion Therapeutics Submits Clinical Trial Application for SIL204 in Phase 2/3 Trial for Locally Advanced Pancreatic Cancer in GermanyApril 28, 2026 | quiverquant.comQSilexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic CancerApril 28, 2026 | globenewswire.comSilexion Therapeutics (SLXN) price target decreased by 33.33% to 6.12March 27, 2026 | msn.comSilexion Therapeutics Announces Immediate Board Membership ChangeMarch 25, 2026 | tipranks.comSilexion Therapeutics Corp: Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced ...March 24, 2026 | finanznachrichten.deSilexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerMarch 24, 2026 | globenewswire.comSilexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerMarch 24, 2026 | globenewswire.comSilexion Therapeutics Corp: Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 20, 2026 | finanznachrichten.deSilexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 17, 2026 | globenewswire.comSilexion Therapeutics to Participate in 7th RNAi-Based Therapeutics Summit Focused on Advancing SIL204 for Pancreatic CancerJanuary 21, 2026 | quiverquant.comQSilexion Therapeutics Corp: Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026January 6, 2026 | finanznachrichten.deSilexion Therapeutics issues letter to shareholdersJanuary 6, 2026 | msn.comSilexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026January 6, 2026 | finance.yahoo.comSilexion Therapeutics Reports Promising Preclinical Results for SIL204 in KRAS-Driven Cancers and Plans Phase 2/3 Trial Initiation for 2026January 6, 2026 | quiverquant.comQSilexion Therapeutics (SLXN) price target decreased by 25.00% to 9.18December 20, 2025 | msn.comSilexion submits phase 2/3 trial application to Israel for SIL204December 16, 2025 | msn.comSilexion Therapeutics Advances Regulatory Submission for Phase 2/3 Trial of SIL204 in Pancreatic CancerDecember 16, 2025 | quiverquant.comQSilexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic CancerDecember 16, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLXN, ATON, GRTX, and LNAI Company DescriptionsPortage Biotech NASDAQ:ATON$0.33 +0.01 (+3.75%) Closing price 04/20/2026Extended Trading$0.33 0.00 (0.00%) As of 04/20/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.Galera Therapeutics NASDAQ:GRTX$0.10 0.00 (0.00%) As of 05/8/2026 02:13 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Lunai Bioworks NASDAQ:LNAI$0.33 0.00 (-0.90%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.31 -0.02 (-4.85%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.Silexion Therapeutics NASDAQ:SLXN$0.52 +0.01 (+1.16%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.53 +0.01 (+1.71%) As of 05/8/2026 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
